WG
PDSB icon

Winton Group’s PDS Biotechnology PDSB Stock Holding History

Winton Group’s Portfolio PDSB Stock Details PDSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-21,256
Closed -$107K – 835
2023
Q3 		$107K Buy
21,256
+4,221
+25% +$23.1K 0.01% 714
2023
Q2 		$85.7K Buy
+17,035
New +$112K 0.01% 725

Other funds holding PDSB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
IWA
Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Winton Group's PDSB Position: Q4 2023 in Review

Winton Group sold out of PDS Biotechnology (PDSB) in Q4 2023, closing a stake of 21,256 shares — an estimated $107K sold.

Winton Group first reported a position in PDSB in Q2 2023 and held it in 2 quarters. The position peaked at $107K in Q3 2023. 77 funds tracked by Wall St. Rank hold PDSB as of Q4 2023.

  • Winton Group reported no remaining PDS Biotechnology position as of Q4 2023 after selling out during the quarter.
  • Winton Group sold 21,256 PDS Biotechnology shares in Q4 2023, an estimated $107K.
  • Winton Group first reported a position in PDS Biotechnology in Q2 2023 and held it in 2 quarters.
  • Winton Group's PDS Biotechnology position peaked at $107K in Q3 2023.
  • 77 funds tracked by Wall St. Rank held PDS Biotechnology as of Q4 2023.

Based on Winton Group's 13F filing for Q4 2023, filed 12 Feb 2024.